This suggests that, as immunity begins to wane, these newly emerging BA.2 variants may fuel future waves of SARS-CoV-2 infection.ĭr Meera Chand, Director of Clinical and Emerging Infection at UKHSA, said: Overall, data shows significant reductions in neutralisation against several of the newly emergent variants (BA.2.75.2, BA.2.3.20 and BJ.1), compared to BA.2, BA.4 and the dominant BA.5. Neutralisation studies are currently being undertaken at the University of Oxford. Currently there are 18 UK samples in GISAID, out of a global total of 1,086 639 samples have been uploaded from Singapore, and it is thought that XBB may be a factor in the recent spike in cases there. XBB (V-22OCT-02) is a recombinant lineage derived from 2 previous Omicron sublineages. So far, there have been 717 V-22OCT-01 sequences uploaded from the UK to the international GISAID database. Neither have currently been designated as variants of concern.īQ.1 (V-22OCT-01) is a BA.5 sub-lineage which has been designated on the basis of rapid growth.
Omicron sublineages BQ.1 and XBB have been given UKHSA variant designations to facilitate continued studies. It contains epidemiological data and updated analysis of COVID-19 variants currently circulating in the UK.Ī number of Omicron variants are currently circulating in England, many of which have acquired mutations which may produce a degree of immune escape. The UK Health Security Agency ( UKHSA) has published its latest COVID-19 variant technical briefing. Friday 28 October 2022 UKHSA designates 2 new COVID-19 variants Vaccination remains our best defence against future COVID-19 waves, so it is still as important as ever that people come take up all the doses for which they are eligible as soon as possible. UKHSA is constantly monitoring the situation and working to understand the implications for public health. Through our genomic surveillance we continue to see evolution of variants in the Omicron family. Neither have been designated as variants of concern by UKHSA.ĭr Meera Chand, Director of Clinical and Emerging Infections, UKHSA, said: The risk assessment conducted by UKHSA together with academic partners found that CH.1.1 and XBB.1.5 are currently the variants most likely to take over from BQ.1 as the next dominant variant in the UK, unless further novel variants arise. XBB.1.5 remains at very low prevalence in the UK, so estimates of growth are highly uncertain. Two variants, CH.1.1 and XBB.1.5, appear to have a growth advantage in the UK.
The analysis shows that coronavirus (COVID-19) cases in the UK are primarily made up of BQ.1 and its sublineages, consistent with the UKHSA risk assessment published in October. The UK Health Security Agency ( UKHSA) has released a new variant technical briefing detailing updated analysis of epidemiological and genomic data relating to SARS-CoV-2 variants currently circulating in the UK, including the XBB.1.5 variant which has been increasing in the US in recent months.
Wednesday 11 January 2023 UKHSA releases updated analysis on XBB.1.5
#SYMPTOMS COVID 19 OMICRON FULL#
The full document and underlying data is available on GOV.UK. The UK Health Security Agency ( UKHSA) has released variant technical briefing 50. The UK Health Security Agency ( UKHSA) has released variant technical briefing 51. The UK Health Security Agency ( UKHSA) has released variant technical briefing 52.
0 kommentar(er)
